BridgeBio Oncology Completes SPAC Merger With Helix, Raises $382M To Advance RAS-Targeted Cancer Therapies; Begins Trading As 'BBOT' On Nasdaq

Benzinga · 08/11/2025 20:35
  • Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 
  • Closed concurrent $261 million private investment in public equity ("PIPE"), led by Cormorant
  • Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the PIPE provides approximately $382 million in gross proceeds
  • Net proceeds will be used to accelerate the development of BBOT's pipeline of clinical-stage RAS-targeted oncology drug candidates
  • BBOT to commence trading on the Nasdaq Global Market under the ticker symbol "BBOT" on August 12, 2025

SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the closing of its previously announced business combination with Helix Acquisition Corp. II (NASDAQ:HLXB) ("Helix"), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management. The business combination was approved by Helix's shareholders on August 4, 2025, and closed on August 11, 2025.

In connection with the closing, Helix changed its name to "BridgeBio Oncology Therapeutics, Inc.", and beginning on August 12, 2025, the shares of common stock of the combined company are expected to begin trading under the new ticker symbol "BBOT" on the Nasdaq Global Market.